The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MNOV Detailed Price Forecast - CNN Money||View MNOV Detailed Summary - Google Finance|
|View MNOV Detailed Summary - Yahoo! Finance||View MNOV Stock Research & Analysis - Zacks.com|
|View MNOV Trends & Analysis - Trade-Ideas||View MNOV Major Holders - Barrons|
|View MNOV Call Transcripts - NASDAQ||View MNOV Breaking News & Analysis - Seeking Alpha|
|View MNOV Annual Report - CompanySpotlight.com||View MNOV OTC Short Report - OTCShortReport.com|
|View MNOV Fundamentals - TradeKing||View MNOV SEC Filings - Bar Chart|
|View Historical Prices for MNOV - The WSJ||View Performance/Total Return for MNOV - Morningstar|
|View the Analyst Estimates for MNOV - MarketWatch||View the Earnings History for MNOV - CNBC|
|View the MNOV Earnings - StockMarketWatch||View MNOV Buy or Sell Recommendations - MacroAxis|
|View the MNOV Bullish Patterns - American Bulls||View MNOV Short Pain Metrics - ShortPainBot.com|
|View MNOV Stock Mentions - StockTwits||View MNOV Stock Mentions - PennyStockTweets|
|View MNOV Stock Mentions - Twitter||View MNOV Investment Forum News - Investor Hub|
|View MNOV Stock Mentions - Yahoo! Message Board||View MNOV Stock Mentions - Seeking Alpha|
|View Insider Transactions for MNOV - SECform4.com||View Insider Transactions for MNOV - Insider Cow|
|View MNOV Major Holdings Summary - CNBC||View Insider Disclosure for MNOV - OTC Markets|
|View Insider Transactions for MNOV - Yahoo! Finance||View Institutional Holdings for MNOV - NASDAQ|
|View MNOV Stock Insight & Charts - FinViz.com||View MNOV Investment Charts - StockCharts.com|
|View MNOV Stock Overview & Charts - BarChart||View MNOV User Generated Charts - Trading View|
MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
Posted on Monday August 06, 2018
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of MN-166 (ibudilast) in degenerative cervical myelopathy (DCM) in collaboration with the University of Cambridge. This clinical trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust.
The oral presentation entitled "Novel Composite Endpoint Extended Analysis during Extension of Ibudilast Phase 1b/2a Clinical Trial Better Predicts Post-Wash-Out Survival” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
Posted on Sunday July 29, 2018
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) is now fully enrolled with 35 subjects. This trial will measure the effect of MN-166 (ibudilast) on reducing brain microglial activation measured by positron emission tomography (PET) imaging using a biomarker and will also evaluate clinical outcomes in ALS subjects. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that this study is now fully enrolled.
MNOV: Plenty of Cash to Advance Pipeline Forward
Posted on Wednesday July 25, 2018
On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.